Fatty acid binding protein 4 (FABP4), cytokeratin 18 (CK-18), and fibroblast growth factor 21 (FGF21) have all emerged as potential circulating biomarkers for NAFLD. This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatotic liver disease.